Dynavax Technologies Net Worth
Dynavax Technologies Net Worth Breakdown | DVAX |
Dynavax Technologies Net Worth Analysis
Dynavax Technologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Dynavax Technologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Dynavax Technologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Dynavax Technologies' net worth analysis. One common approach is to calculate Dynavax Technologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Dynavax Technologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Dynavax Technologies' net worth. This approach calculates the present value of Dynavax Technologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Dynavax Technologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Dynavax Technologies' net worth. This involves comparing Dynavax Technologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Dynavax Technologies' net worth relative to its peers.
To determine if Dynavax Technologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dynavax Technologies' net worth research are outlined below:
| Dynavax Technologies has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: High Growth Tech Stocks to Watch in the US July 2025 - simplywall.st |
Dynavax Technologies Quarterly Good Will |
|
Dynavax Technologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dynavax Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dynavax Technologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Dynavax Technologies Target Price Consensus
Dynavax target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dynavax Technologies' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Buy |
Most Dynavax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dynavax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dynavax Technologies, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDynavax Technologies Target Price Projection
Dynavax Technologies' current and average target prices are 11.36 and 23.27, respectively. The current price of Dynavax Technologies is the price at which Dynavax Technologies is currently trading. On the other hand, Dynavax Technologies' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dynavax Technologies Market Quote on 27th of July 2025
Target Price
Analyst Consensus On Dynavax Technologies Target Price
Know Dynavax Technologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dynavax Technologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dynavax Technologies backward and forwards among themselves. Dynavax Technologies' institutional investor refers to the entity that pools money to purchase Dynavax Technologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | D. E. Shaw & Co Lp | 2025-03-31 | 2.5 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 2.5 M | Blair William & Co | 2025-03-31 | 2.3 M | Amvescap Plc. | 2025-03-31 | 2.2 M | Northern Trust Corp | 2025-03-31 | 1.4 M | Two Sigma Investments Llc | 2025-03-31 | 1.3 M | Goldman Sachs Group Inc | 2025-03-31 | 1.3 M | Woodline Partners Lp | 2025-03-31 | 1.2 M | Charles Schwab Investment Management Inc | 2025-03-31 | 1.2 M | Blackrock Inc | 2025-03-31 | 20.3 M | Deep Track Capital, Lp | 2025-03-31 | 17.8 M |
Follow Dynavax Technologies' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.36 B.Market Cap |
|
Project Dynavax Technologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
When accessing Dynavax Technologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Dynavax Technologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dynavax Technologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Dynavax Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dynavax Technologies. Check Dynavax Technologies' Beneish M Score to see the likelihood of Dynavax Technologies' management manipulating its earnings.
Evaluate Dynavax Technologies' management efficiency
At this time, Dynavax Technologies' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.03 in 2025, whereas Return On Capital Employed is likely to drop (0) in 2025. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 22.2 M in 2025, whereas Other Assets are likely to drop slightly above 3 M in 2025. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.59 | 4.82 | |
| Tangible Book Value Per Share | 4.57 | 4.80 | |
| Enterprise Value Over EBITDA | 39.81 | 41.80 | |
| Price Book Value Ratio | 2.78 | 4.39 | |
| Enterprise Value Multiple | 39.81 | 41.80 | |
| Price Fair Value | 2.78 | 4.39 | |
| Enterprise Value | 356.6 M | 317 M |
Evaluating the management effectiveness of Dynavax Technologies allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Dynavax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 3.2747 | Revenue | Quarterly Revenue Growth 0.342 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dynavax Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dynavax Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dynavax Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dynavax Technologies Corporate Filings
| 17th of July 2025 Other Reports | ViewVerify | |
8K | 17th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 9th of June 2025 Other Reports | ViewVerify |
Dynavax Technologies Earnings Estimation Breakdown
The calculation of Dynavax Technologies' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Dynavax Technologies is estimated to be -0.105 with the future projection ranging from a low of -0.105 to a high of -0.105. Please be aware that this consensus of annual earnings estimates for Dynavax Technologies is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.1 Lowest | Expected EPS | -0.1 Highest |
Dynavax Technologies Earnings Projection Consensus
Suppose the current estimates of Dynavax Technologies' value are higher than the current market price of the Dynavax Technologies stock. In this case, investors may conclude that Dynavax Technologies is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Dynavax Technologies' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 55.8% | 0.0 | -0.105 | -0.5 |
Dynavax Technologies Earnings per Share Projection vs Actual
Actual Earning per Share of Dynavax Technologies refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Dynavax Technologies predict the company's earnings will be in the future. The higher the earnings per share of Dynavax Technologies, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Dynavax Technologies Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Dynavax Technologies, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Dynavax Technologies should always be considered in relation to other companies to make a more educated investment decision.Dynavax Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Dynavax Technologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | 0.0123 | -0.0091 | -0.0214 | 173 | ||
2025-02-20 | 2024-12-31 | 0.04 | 0.05 | 0.01 | 25 | ||
2024-11-07 | 2024-09-30 | 0.11 | 0.12 | 0.01 | 9 | ||
2024-08-06 | 2024-06-30 | 0.06 | 0.08 | 0.02 | 33 | ||
2024-05-08 | 2024-03-31 | -0.02 | -0.07 | -0.05 | 250 | ||
2024-02-22 | 2023-12-31 | -0.01 | 0.0016 | 0.0116 | 116 | ||
2023-11-02 | 2023-09-30 | -0.01 | 0.1 | 0.11 | 1100 | ||
2023-08-03 | 2023-06-30 | -0.09 | 0.03 | 0.12 | 133 | ||
2023-05-02 | 2023-03-31 | -0.13 | -0.19 | -0.06 | 46 | ||
2023-02-23 | 2022-12-31 | 0.43 | 0.45 | 0.02 | 4 | ||
2022-11-03 | 2022-09-30 | 0.33 | 0.43 | 0.1 | 30 | ||
2022-08-04 | 2022-06-30 | 0.22 | 0.87 | 0.65 | 295 | ||
2022-05-05 | 2022-03-31 | 0.24 | 0.22 | -0.02 | 8 | ||
2022-02-28 | 2021-12-31 | 0.64 | 0.55 | -0.09 | 14 | ||
2021-11-04 | 2021-09-30 | 0.05 | -0.24 | -0.29 | 580 | ||
2021-08-04 | 2021-06-30 | -0.04 | 0.02 | 0.06 | 150 | ||
2021-05-06 | 2021-03-31 | -0.02 | 0.01 | 0.03 | 150 | ||
2021-02-25 | 2020-12-31 | -0.24 | -0.14 | 0.1 | 41 | ||
2020-11-05 | 2020-09-30 | -0.2 | -0.02 | 0.18 | 90 | ||
2020-08-06 | 2020-06-30 | -0.24 | -0.53 | -0.29 | 120 | ||
2020-05-07 | 2020-03-31 | -0.31 | -0.15 | 0.16 | 51 | ||
2020-03-11 | 2019-12-31 | -0.33 | -0.44 | -0.11 | 33 | ||
2019-11-06 | 2019-09-30 | -0.39 | -0.5 | -0.11 | 28 | ||
2019-08-07 | 2019-06-30 | -0.56 | -0.52 | 0.04 | 7 | ||
2019-05-08 | 2019-03-31 | -0.65 | -0.62 | 0.03 | 4 | ||
2019-02-26 | 2018-12-31 | -0.61 | -0.64 | -0.03 | 4 | ||
2018-11-05 | 2018-09-30 | -0.57 | -0.65 | -0.08 | 14 | ||
2018-08-06 | 2018-06-30 | -0.63 | -0.63 | 0.0 | 0 | ||
2018-05-08 | 2018-03-31 | -0.49 | -0.63 | -0.14 | 28 | ||
2018-03-08 | 2017-12-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2017-11-03 | 2017-09-30 | -0.47 | -0.38 | 0.09 | 19 | ||
2017-08-02 | 2017-06-30 | -0.44 | -0.41 | 0.03 | 6 | ||
2017-05-08 | 2017-03-31 | -0.51 | -0.6 | -0.09 | 17 | ||
2017-03-13 | 2016-12-31 | -0.85 | -0.56 | 0.29 | 34 | ||
2016-11-07 | 2016-09-30 | -0.75 | -0.9 | -0.15 | 20 | ||
2016-08-05 | 2016-06-30 | -0.68 | -0.75 | -0.07 | 10 | ||
2016-05-09 | 2016-03-31 | -0.63 | -0.7 | -0.07 | 11 | ||
2016-03-08 | 2015-12-31 | -0.74 | -0.7 | 0.04 | 5 | ||
2015-11-05 | 2015-09-30 | -0.78 | -0.82 | -0.04 | 5 | ||
2015-08-07 | 2015-06-30 | -0.99 | -0.8 | 0.19 | 19 | ||
2015-05-07 | 2015-03-31 | -0.95 | -0.97 | -0.02 | 2 | ||
2015-03-05 | 2014-12-31 | -0.96 | -0.85 | 0.11 | 11 | ||
2014-11-05 | 2014-09-30 | -0.94 | -1.1 | -0.16 | 17 | ||
2014-08-07 | 2014-06-30 | -0.62 | -0.9 | -0.28 | 45 | ||
2014-05-05 | 2014-03-31 | -0.62 | -0.5 | 0.12 | 19 | ||
2014-03-10 | 2013-12-31 | -0.74 | -0.6 | 0.14 | 18 | ||
2013-11-07 | 2013-09-30 | -1.02 | -0.9 | 0.12 | 11 | ||
2013-07-29 | 2013-06-30 | -0.97 | -0.9 | 0.07 | 7 | ||
2013-05-06 | 2013-03-31 | -0.92 | -1.1 | -0.18 | 19 | ||
2013-03-01 | 2012-12-31 | -0.77 | -1.1 | -0.33 | 42 | ||
2012-11-01 | 2012-09-30 | -0.82 | -1.0 | -0.18 | 21 | ||
2012-08-01 | 2012-06-30 | -0.95 | -0.9 | 0.05 | 5 | ||
2012-04-27 | 2012-03-31 | -0.95 | -1.1 | -0.15 | 15 | ||
2012-03-06 | 2011-12-31 | -0.74 | -0.3 | 0.44 | 59 | ||
2011-10-27 | 2011-09-30 | -1.25 | -1.2 | 0.05 | 4 | ||
2011-07-20 | 2011-06-30 | -1.07 | -0.9 | 0.17 | 15 | ||
2011-05-05 | 2011-03-31 | -1.43 | -1.6 | -0.17 | 11 | ||
2011-03-08 | 2010-12-31 | -1.5 | -1.4 | 0.1 | 6 | ||
2010-11-04 | 2010-09-30 | -0.3 | -0.6 | -0.3 | 100 | ||
2010-07-30 | 2010-06-30 | -1.3 | -3.4 | -2.1 | 161 | ||
2010-03-16 | 2009-12-31 | -2.3 | -7.3 | -5.0 | 217 | ||
2009-10-22 | 2009-09-30 | -1.6 | -2.4 | -0.8 | 50 | ||
2009-08-04 | 2009-06-30 | 0.45 | 1.0 | 0.55 | 122 | ||
2009-04-28 | 2009-03-31 | -1.5 | 1.3 | 2.8 | 186 | ||
2009-03-02 | 2008-12-31 | -0.8 | 0.8 | 1.6 | 200 | ||
2008-11-03 | 2008-09-30 | -1.4 | -1.4 | 0.0 | 0 | ||
2008-08-05 | 2008-06-30 | -2.62 | -1.5 | 1.12 | 42 | ||
2008-04-29 | 2008-03-31 | -2.63 | -3.1 | -0.47 | 17 | ||
2008-02-19 | 2007-12-31 | -3.32 | -3.0 | 0.32 | 9 | ||
2007-11-01 | 2007-09-30 | -3.75 | -4.3 | -0.55 | 14 | ||
2007-07-31 | 2007-06-30 | -1.48 | -4.5 | -3.02 | 204 | ||
2007-05-02 | 2007-03-31 | -2.92 | -3.3 | -0.38 | 13 | ||
2007-02-13 | 2006-12-31 | -3.62 | -4.4 | -0.78 | 21 | ||
2006-10-26 | 2006-09-30 | -3.6 | -4.0 | -0.4 | 11 | ||
2006-07-27 | 2006-06-30 | -2.9 | -5.0 | -2.1 | 72 | ||
2006-04-27 | 2006-03-31 | -3.37 | -2.7 | 0.67 | 19 | ||
2006-03-15 | 2005-12-31 | -3.86 | -3.0 | 0.86 | 22 | ||
2005-10-27 | 2005-09-30 | -4.05 | -3.3 | 0.75 | 18 | ||
2005-07-28 | 2005-06-30 | -3.53 | -3.5 | 0.03 | 0 | ||
2005-04-28 | 2005-03-31 | -1.2 | 2.0 | 3.2 | 266 | ||
2005-02-15 | 2004-12-31 | -1.97 | -2.1 | -0.13 | 6 | ||
2004-11-08 | 2004-09-30 | -2 | -1.6 | 0.4 | 20 | ||
2004-08-05 | 2004-06-30 | -1.7 | -1.2 | 0.5 | 29 | ||
2004-05-04 | 2004-03-31 | -1.6 | -3.6 | -2.0 | 125 |
Dynavax Technologies Corporate Management
| David Novack | Sr. VP of Operations and Quality | Profile | |
| Eric Frings | Site VP | Profile | |
| Joe Metzinger | VP Officer | Profile | |
| Robert MD | Medical Development | Profile | |
| Donn Casale | Senior Officer | Profile |
Additional Tools for Dynavax Stock Analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.